Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Jupiter Neurosciences Inc (JUNS)

Jupiter Neurosciences Inc (JUNS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 15,595
  • Shares Outstanding, K 34,426
  • Annual Sales, $ 0 K
  • Annual Income, $ -2,440 K
  • EBIT $ -8 M
  • EBITDA $ -8 M
  • 60-Month Beta 2.62
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.24
  • Most Recent Earnings $-0.07 on 11/14/25
  • Next Earnings Date 03/27/26 [--]
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.07
  • Number of Estimates 1
  • High Estimate -0.07
  • Low Estimate -0.07
  • Prior Year -0.05
  • Growth Rate Est. (year over year) -40.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4305 +4.53%
on 03/04/26
0.6300 -28.57%
on 02/10/26
-0.1657 (-26.91%)
since 02/05/26
3-Month
0.4305 +4.53%
on 03/04/26
1.2900 -65.12%
on 12/11/25
-0.6900 (-60.53%)
since 12/05/25
52-Week
0.4305 +4.53%
on 03/04/26
3.3300 -86.49%
on 07/15/25
-0.1920 (-29.91%)
since 03/05/25

Most Recent Stories

More News
Jupiter Neurosciences to Present at BIO Investment and Growth Summit 2026

Advancing FDA-Cleared Phase IIa Parkinson’s Program Targeting Neuroinflammation Dual-Path Strategy Combines Clinical Development with Revenue-Generating Nugevia ™ JUPITER, FL, March 02,...

JUNS : 0.4500 (-0.66%)
Jupiter Neurosciences Invited to Present Clinical and Commercial Progress at Investor Dinner at Mar-a-Lago

JUPITER, FL, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company focused on neuroinflammation and central...

JUNS : 0.4500 (-0.66%)
Jupiter Neurosciences Amends Yorkville Installment Provisions to Align Capital With Clinical and Commercial Execution

Repayment Commencement Deferred to April 1, 2026 Core Economic Terms of $6.0 Million Financing Remain Unchanged JUPITER, FL, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:...

JUNS : 0.4500 (-0.66%)
Jupiter Neurosciences Expands Nugevia™ Addressable Market with Focus on GLP-1 Users

Nugevia ™ supports metabolic, mitochondrial, and neuroinflammatory biology impacted by GLP-1-driven weight loss Jupiter, Florida, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences,...

JUNS : 0.4500 (-0.66%)
Join Jupiter Neurosciences’ Exclusive Live Investor Webinar and Q&A Session on January 6

Jupiter, Florida, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company developing JOTROL ™ , a...

JUNS : 0.4500 (-0.66%)
Jupiter Neurosciences Marks Transformational First Year as a Public Company, Entering 2026 with Powerful Clinical and Commercial Momentum

Company advances JOTROL ™ into Phase 2a Parkinson’s trial, launches Nugevia ™ consumer brand, and strengthens financial position Jupiter, Florida, Dec. 03, 2025 (GLOBE NEWSWIRE)...

JUNS : 0.4500 (-0.66%)
Jupiter Neurosciences Receives FDA Clearance of IND Application to Initiate Phase 2a Clinical Trial of JOTROL™ in Parkinson’s Disease

Jupiter, Florida, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS), a clinical-stage pharmaceutical company developing JOTROL ™ , a patented resveratrol-based therapeutic...

JUNS : 0.4500 (-0.66%)
Jupiter Neurosciences Enters into Agreements for up to $20 Million in Flexible Financing

Financing designed to support Phase 2 Parkinson’s trial and accelerate Nugevia ™ product line growth Jupiter, FL, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc (“JUNS”...

JUNS : 0.4500 (-0.66%)
Jupiter Neurosciences Names Visionary Entrepreneur and Biohacker Jean Fallacara as Third Nugevia™ Brand Ambassador

Partnership strengthens Nugevia ™ launch bringing clinical and scientific integrity to the fast-growing longevity space Jupiter, Florida, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Jupiter...

JUNS : 0.4500 (-0.66%)
Jupiter Neurosciences Launches Nugevia™ Website and Opens Pre-Orders for Groundbreaking Longevity Supplements

Targeting the Multi-Trillion Dollar Longevity Market Jupiter, Florida, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage...

JUNS : 0.4500 (-0.66%)

Business Summary

Jupiter Neurosciences Inc. is a clinical-stage pharmaceutical company focused on treating neuroinflammation, with a current focus on CNS disorders and rare diseases. The Company's pipeline is focused broadly on CNS disorder and includes indications such as Alzheimer's Disease, Parkinson's Disease, Mucopolysaccharidoses...

See More

Key Turning Points

3rd Resistance Point 0.5195
2nd Resistance Point 0.4972
1st Resistance Point 0.4751
Last Price 0.4500
1st Support Level 0.4307
2nd Support Level 0.4084
3rd Support Level 0.3863

See More

52-Week High 3.3300
Fibonacci 61.8% 2.2224
Fibonacci 50% 1.8802
Fibonacci 38.2% 1.5381
Last Price 0.4500
52-Week Low 0.4305

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar